Russell MO, Goldberg HI, Hodson A, Kim HC, Halus J, Reivich M, Schwartz E. Effect of transfusion therapy on arteriographic abnormalities and on re- currence of stroke in sickle cell disease. Blood. 1984;63:162 169. 657. Pegelow CH, Adams RJ, McKie V, Abboud M, Berman B, Miller ST, Olivieri N, Vichinsky E, Wang W, Brambilla D. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr. 658. Estcourt LJ, Fortin PM, Hopewell S, Trivella M, Wang WC. Blood trans- fusion for preventing primary and secondary stroke in people with sick- le cell disease. Cochrane Database Syst Rev. 2017;1:CD003146. doi: 659. Ware RE, Helms RW; SWiTCH Investigators. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood. 2012;119:3925 3932. doi: 660. Ali SB, Moosang M, King L, Knight-Madden J, Reid M. Stroke recurrence in children with sickle cell disease treated with hydroxyurea following first clinical stroke. Am J Hematol. 2011;86:846 850. doi: 10.1002/ajh.22142 661. Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, et al. Hydroxycarbamide versus chronic trans- fusion for maintenance of transcranial Doppler flow velocities in children with sickle cell anaemia: TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 662. Lucarelli G, Gaziev J, Isgr A, Sodani P, Paciaroni K, Alfieri C, De Angelis G, Marziali M, Simone MD, Gallucci C, et al. Allogeneic cellular gene therapy in hemoglobinopathies: evaluation of hematopoietic SCT in sickle cell anemia. Bone Marrow Transplant. 2012;47:227 230. doi: 10.1038/bmt.2011.79 663. Walters MC, Patience M, Leisenring W, Rogers ZR, Aquino VM, Buchanan GR, Roberts IA, Yeager AM, Hsu L, Adamkiewicz T, et al; Multicenter Investigation of Bone Marrow Transplantation for Sickle Cell Disease. 